SCHEMBL14906579

SCHEMBL14906579

c1ccc(-c2nc3ccc(-c4nc5ccc(N6CCOCC6)cc5[nH]4)cc3[nH]2)nc1

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CBFB Q13951 6/20 0.89
FGFR1 P11362 2/20 0.55
FLT1 P17948 2/20 0.55
SMN1; SMN2 Q16637 4/20 0.52
NPC1 O15118 3/20 0.52
PKM P14618 3/20 0.52
RAB9A P51151 3/20 0.52
MAPT P10636 3/20 0.52
KDM4E B2RXH2 2/20 0.52
LMNA P02545 2/20 0.52
KMT2A Q03164 2/20 0.52
METAP2 P50579 5/20 0.52
METAP1 P53582 3/20 0.52
HPGD P15428 2/20 0.52
TP53 P04637 1/20 0.52
GAA P10253 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
TOP1 P11387 2/20 0.52
TOP2A P11388 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2565858 0.90 CBFB (0.76) CBFBFGFR1FLT1SMN1; SMN2NPC1
SCHEMBL14906739 0.90 CBFB (0.72) CBFBFGFR1SMN1; SMN2NPC1PKM
SCHEMBL12289536 0.88 CBFB (0.69) CBFBSMN1; SMN2NPC1PKMRAB9A
SCHEMBL14906575 0.88 CBFB (0.69) CBFBFGFR1FLT1SMN1; SMN2NPC1
SCHEMBL124347 0.86 CBFB (0.84) CBFBFGFR1FLT1SMN1; SMN2NPC1
SCHEMBL14906737 0.86 CBFB (0.67) CBFBSMN1; SMN2NPC1PKMRAB9A
SCHEMBL14906547 0.86 CBFB (0.67) CBFBSMN1; SMN2NPC1PKMRAB9A
SCHEMBL14906586 0.86 CBFB (0.66) CBFBFGFR1FLT1SMN1; SMN2NPC1
SCHEMBL12288112 0.85 CBFB (0.66) CBFBSMN1; SMN2NPC1PKMRAB9A
SCHEMBL14906544 0.85 CBFB (0.65) CBFBFGFR1FLT1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE46943-E1 Radioprotector compounds and methods PETER MACCALLUM CANCER INSTITUTE (AU) 2018-07-10 US disclosed
EP-2556058-B1 RADIOPROTECTOR COMPOUNDS AND METHODS PETER MACCALLUM CANCER INST (AU) 2017-06-14 EP disclosed
US-8999993-B2 Radioprotector compounds and methods PETER MACCALLUM CANCER INSTITUTE (AU) 2015-04-07 US disclosed
US-20130109678-A1 RADIOPROTECTOR COMPOUNDS AND METHODS PETER MACCALLUM CANCER INSTITUTE (AU) 2013-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109678-A1 RADIOPROTECTOR COMPOUNDS AND METHODS NR1H2, NR1H3, NR1I3 CBFB 688/4885FGFR1 3187/4885FLT1 3852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.